Glioblastoma of the Conus Medullaris Following Treatment of Hodgkin's Lymphoma: History of a Case and Literature ReviewPichon B1, Champiat S2,4, Aumont M1, Loussouarn D3, Frénel JS4, Mahé MA1 and Demoor-Goldschmidt C1,5-7*
- *Corresponding Author:
- Demoor-Goldschmidt C
Department of Radiotherapy
Institut de Cancérologie de l'Ouest- René Gauducheau
Bd J Monod, 44800, Nantes, St- Herblain, France
Fax: +33 (0) 240679722
E-mail: [email protected]
Received Date: March 09, 2017; Accepted Date: March 22, 2017; Published Date: March 27, 2017
Citation: Pichon B, Champiat S, Aumont M, Loussouarn D, Frénel JS, et al. (2017) Glioblastoma of the Conus Medullaris Following Treatment of Hodgkin's Lymphoma: History of a Case and Literature Review. OMICS J Radiol 6:257. doi: 10.4172/2167-7964.1000257
Copyright: © 2017 Pichon B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Purpose: Reports of a glioblastoma arising in a previously irradiated field are rare in the literature, even more so in the conus medullaris of the spinal cord. Method: Case report and review of the literature reporting other radiation-induced intra-medullary glioblastomas. Results: We report a case of glioblastoma of the conus, which subsequently metastasized to the brain, arising in a 45 years old man, nine years after treatment for Hodgkin's lymphoma, which had included the administration of 41 Gy to the brain and spinal cord. Conclusion: Despite a well-conducted treatment by several lines of chemotherapy, the pronostic of radiationinduced glioblastoma is poor especially since these patients often cannot benefit from a re-irradiation due to the maximum dose supported by the spinal cord. Implications of cancer survivors: Associations are now established between therapeutic exposures and specific complications but considerable inter-individual variability is observed for a given therapeutic exposure. In this context, identification of genetic susceptibilities for specific treatment-associated late effect is a very promising future approach. Improvement in our knowledge on genetic susceptibilities may help define more personalized primary therapies that weigh treatment efficacy with the risk of late complications.